Characterization of sleep habits and medication outcomes for sleep disturbance in children and adults with Angelman syndrome

被引:11
作者
Pereira, Joseph A. [1 ]
Ravichandran, Caitlin T. [1 ,2 ,3 ]
Mullett, Jennifer [2 ]
McDougle, Christopher J. [1 ,2 ,4 ]
Keary, Christopher J. [1 ,2 ,4 ]
机构
[1] Harvard Med Sch, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Lurie Ctr Autism, Lexington, MA USA
[3] McLean Hosp, 115 Mill St, Belmont, MA 02178 USA
[4] Massachusetts Gen Hosp Children, Angelman Syndrome Program, Boston, MA USA
关键词
Angelman syndrome; clonidine; melatonin; sleep disturbance; trazodone; NEURODEVELOPMENTAL DISORDERS; EPILEPSY; QUESTIONNAIRE; ADOLESCENTS; PHENOTYPES; CLONIDINE;
D O I
10.1002/ajmg.a.61642
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The objectives of this study were to characterize the sleep habits of 50 clinically referred individuals with Angelman syndrome (AS) and to retrospectively compare the effectiveness/tolerability of the three most commonly prescribed sleep medications in the sample. An experienced physician assigned a Clinical Global Impressions-Severity scale (CGI-S) score for each subject's AS-specific symptoms. Caregivers completed the Child Sleep Habits Questionnaire (CSHQ; screen for sleep problems in school-aged [4-10 years] children), a screening assessment for sleep problems. Caregivers provided information about medication trials targeting disturbed sleep, with the physician assigning a CGI-Improvement scale (CGI-I) score for each trial. Linear regression showed significant negative association between age and CSHQ score. In their lifetime, 72% of participants had taken a medication for sleep, most commonly melatonin, clonidine and trazodone. The majority continued these for 6 months or longer. With these medications, many demonstrated significant improvement in sleep disturbances, with no difference in odds of improvement between medications. Disturbed sleep was common in this cohort and significantly worse in younger-aged participants. The majority received at least one medication trial for disturbed sleep and each of the most commonly prescribed medication was effective for a substantial percentage of participants. Most participants remained on medication for at least 6 months, suggesting favorable tolerability.
引用
收藏
页码:1913 / 1922
页数:10
相关论文
共 40 条
[11]  
Didden R, 2004, AM J MENT RETARD, V109, P275, DOI 10.1352/0895-8017(2004)109<275:SPIIWS>2.0.CO
[12]  
2
[13]  
DuBuske LM, 1996, J ALLERGY CLIN IMMUN, V98, pS307, DOI 10.1016/S0091-6749(96)70058-1
[14]   Sleep in children and adolescents with Angelman syndrome: association with parent sleep and stress [J].
Goldman, S. E. ;
Bichell, T. J. ;
Surdyka, K. ;
Malow, B. A. .
JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2012, 56 (06) :600-608
[15]   The children's sleep habits questionnaire in toddlers and preschool children [J].
Goodlin-Jones, Beth L. ;
Sitnick, Stephanie L. ;
Tang, Karen ;
Liu, Jingyi ;
Anders, Thomas F. .
JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2008, 29 (02) :82-88
[16]   Psychological well-being in parents of children with Angelman, Cornelia de Lange and Cri du Chat syndromes [J].
Griffith, G. M. ;
Hastings, R. P. ;
Oliver, C. ;
Howlin, P. ;
Moss, J. ;
Petty, J. ;
Tunnicliffe, P. .
JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2011, 55 :397-410
[17]   Pharmacological treatment of sleep disturbance in developmental disabilities: A review of the literature [J].
Hollway, Jill A. ;
Aman, Michael G. .
RESEARCH IN DEVELOPMENTAL DISABILITIES, 2011, 32 (03) :939-962
[18]   The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders - A case series [J].
Ingrassia, A ;
Turk, J .
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2005, 14 (01) :34-40
[19]   UBE3A/E6-AP mutations cause Angelman syndrome [J].
Kishino, T ;
Lalande, M ;
Wagstaff, J .
NATURE GENETICS, 1997, 15 (01) :70-73
[20]   Tetrahydrobiopterin as a Treatment for Autism Spectrum Disorders: A Double-Blind, Placebo-Controlled Trial [J].
Klaiman, Cheryl ;
Huffman, Lynne ;
Masaki, Lauren ;
Elliott, Glen R. .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2013, 23 (05) :320-328